Use of megestrol acetate for improving heart function and the treatment of heart insufficiency
View Patent ↗The present invention relates to improving the heart function, the survival and/or the treatment of heart insufficiency using megestrol acetate (Megace®; MA) in patients with heart insufficiency and after a myocardial infarction.
1. A method for improving cardiac function and/or the treatment of chronic heart insufficiency in a mammal, wherein said method consists of administering to said mammal an effective amount of megestrol acetate or a pharmaceutically acceptable salt thereof in combination with a diuretic agent, and, optionally, one or more agents selected from the group consisting of vasodilators, digitalis, ACE-inhibitors, angiotensin-II receptor antagonists, beta-blockers, endothelin receptor antagonists, xanthin oxidase inhibitors, statins (HMG-CoA reductase inhibitors), bile-acid resins, cholesterol absorption inhibitors, nicotinic acid, and fabric acid derivatives.
2. The method, according to claim 1 , wherein said mammal is a human.
3. The method, according to claim 1 , wherein said megestrol acetate is selected from a megestrol acetate oral suspension and/or a microcrystalline formulation of a megestrol acetate oral suspension.
4. The method, according to claim 1 , wherein said chronic heart insufficiency is resulting from a -cardiomyopathy.
5. The method, according to claim 4 , wherein said chronic heart insufficiency is resulting from a cardiomyopathy due to myocardial infarction.
6. The method, according to claim 1 , wherein said effective amount of megestrol acetate or pharmaceutically acceptable salt thereof is applied orally.
7. The method, according to claim 1 , wherein said megestrol acetate or a pharmaceutically acceptable salt thereof is applied in a dosage of between 30 mg/d and 2000 mg/d.
8. The method, according to claim 1 , wherein said megestrol acetate or a pharmaceutically acceptable salt thereof is applied in a dosage of between 4 and 15 mg/kg/d.
9. The method, according to claim 7 , wherein said megestrol acetate or a pharmaceutically acceptable salt thereof is applied in a dosage of between 100 mg/d and 1600 mg/d.
10. The method, according to claim 7 , wherein said megestrol acetate or a pharmaceutically acceptable salt thereof is applied in a dosage of between 300 mg/d and 800 mg/d.
11. The method, according to claim 1 , wherein said diuretic agent is furosemide.
12. A method for improving cardiac function and/or the treatment of chronic heart insufficiency in a mammal, wherein said method consists of administering to the mammal an effective amount of megestrol acetate or a pharmaceutically acceptable salt thereof in combination with a diuretic agent.
13. The method, according to claim 12 , wherein said mammal is a human.
14. The method, according to claim 12 , wherein said megestrol acetate is selected from a megestrol acetate oral suspension and/or a microcrystalline formulation of a megestrol acetate oral suspension.
15. The method, according to claim 12 , wherein said chronic heart insufficiency is resulting from a cardiomyopathy.
16. The method, according to claim 12 , wherein said chronic heart insufficiency is resulting from a cardiomyopathy due to myocardial infarction.
17. The method, according to claim 12 , wherein said effective amount of megestrol acetate or a pharmaceutically acceptable salt thereof is applied orally.
18. The method, according to claim 12 , wherein said megestrol acetate or a pharmaceutically acceptable salt thereof is applied in a dosage of between 30 mg/d and 2000 mg/d.
19. The method, according to claim 1 , wherein said megestrol acetate or a pharmaceutically acceptable salt thereof is applied in a dosage of between 4 and 15 mg/kg/d.